(CercleFinance.com) – Abionyx Pharma wins 5% after the presentation of positive interim results in the phase 2a clinical trial evaluating CER-001 in the treatment of patients with sepsis at high risk of developing acute kidney injury.
Compared to standard treatment, CER-001 rapidly improved biomarkers of inflammation, including leukocytosis, as well as endothelial dysfunction, preventing the decline of septic patients to acute kidney injury.
‘CER-001 treatment was well tolerated at all doses administered. No severe treatment-related side effects were observed in this critically ill patient population.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
